Nurix Therapeutics Inc (NRIX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.61B
Last updated: Nov 17, 2026 at 4:25 PM ET
Nurix Therapeutics Inc (NRIX) Statistics
Nurix Therapeutics (NRIX) has a market cap of $1.61B and an enterprise value of $889.01M. Revenue grew 738.76% over the last 12 months from the 12 months before. Its share count is up 32.56% from a year earlier.
Total Valuation
Enterprise value is 44.76% below the market cap, as cash exceeds debt.
| Market Cap | $1.61B |
|---|---|
| Enterprise Value | $889.01M |
| Latest price (Nov 17, 2026) | $14.24 |
Key Dates
The next earnings report is expected on Jan 26, 2027, covering the quarter ending Nov 30, 2026.
| Next Earnings Date | Jan 26, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 12, 2026 |
| Fiscal Year End | November |
Valuation Ratios
Sales and book value multiples are 2.3x and 1.6x.
| P/E Ratio | 6.2x |
|---|---|
| Forward P/E | 5.3x |
| P/S Ratio | 2.3x |
| Forward P/S | 2.2x |
| P/B Ratio | 1.6x |
| P/FCF Ratio | 4.3x |
| P/OCF Ratio | 4.2x |
Enterprise Valuation
Counting debt and cash, the company is valued at 2.9x EBITDA and 2.3x free cash flow.
| EV / Earnings | 3.0x |
|---|---|
| EV / Sales | 1.3x |
| EV / EBITDA | 2.9x |
| EV / FCF | 2.3x |
Price Statistics
The stock is up 11.25% over 52 weeks and trades 37.54% below its 50-day average.
| Beta (1Y) | 1.02 |
|---|---|
| 52-Week Change | +11.25% |
| 1-Month Change | -42.88% |
| 3-Month Change | -48.76% |
| 6-Month Change | -6.56% |
| 5-Year Change | -19.88% |
| Total Return (1Y) | +11.25% |
| Total Return (3Y CAGR) | +31.23% |
| Total Return (5Y CAGR) | -15.45% |
| Return vs SPY (1Y) | +0.74% |
| Max Drawdown (1Y) | -48.76% |
| Max Drawdown (3Y) | -70.72% |
| Sharpe Ratio (1Y) | 0.16 |
| Correlation with SPY (1Y) | 0.19 |
| 50-Day Average | $22.80 |
| 200-Day Average | $20.10 |
| 52-Week Range | $12.61 to $28.23 |
| RSI (14 Days) | 24.1 |
| Average Volume (20 Days) | 3.77M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 8.44x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 8.44x |
|---|---|
| Quick Ratio | 8.44x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is 30.45% over the last 12 months, against a 5-year average of -50.25%.
| Return on Equity (ROE) | 30.45% |
|---|---|
| Return on Assets (ROA) | 24.67% |
| ROE (5Y Average) | -50.25% |
| ROA (5Y Average) | -35.14% |
| ROIC (5Y Average) | -53.02% |
| Asset Turnover | 0.82x |
| Receivables Turnover | 70.19x |
Taxes
Income tax took 4.33% of pretax income over the last 12 months.
| Income Tax (TTM) | $13.34M |
|---|---|
| Effective Tax Rate | 4.33% |
Scores
NRIX has an Altman Z-Score of 5.83, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 5.83 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $701.94M over the last 12 months.
| Revenue | $701.94M |
|---|---|
| Revenue Growth (YoY) | +738.76% |
| Gross Profit | $701.94M |
| Operating Income | $289.66M |
| Pretax Income | $308.21M |
| Net Income | $294.88M |
| Reported EPS (TTM) | $2.31 |
Trailing 12 months through Aug 31, 2026.
Balance Sheet
Shareholder equity funds 80.69% of the $1.20B in total assets.
| Cash and Equivalents | $720.24M |
|---|---|
| Total Debt | $0 |
| Net Cash | $720.24M |
| Net Cash Per Share | $6.46 |
| Working Capital | $972.95M |
| Shareholder Equity | $968.31M |
| Book Value Per Share | $8.68 |
| Total Assets | $1.20B |
| Total Liabilities | $226.99M |
Balance sheet as of Aug 31, 2026.
Cash Flow
After $9.50M of capital spending, operating cash flow left $369.81M of free cash flow.
| Operating Cash Flow | $379.31M |
|---|---|
| Capital Expenditures | $9.50M |
| Free Cash Flow | $369.81M |
| FCF Per Share | $3.56 |
| Depreciation and Amortization | $10.33M |
Trailing 12 months through Aug 31, 2026.
Margins
The operating margin is 41.27%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | 41.27% |
| Pretax Margin | 43.91% |
| Net Margin | 42.01% |
| FCF Margin | 52.68% |
Growth
Revenue grew 29.55% a year over 3 years.
| Revenue Growth (3Y CAGR) | +29.55% |
|---|---|
| Revenue Growth (5Y CAGR) | +36.35% |
| Book Value Per Share Growth (2Y CAGR) | +24.29% |
| Tangible Book Per Share Growth (2Y CAGR) | +24.29% |
Dividends and Yields
NRIX does not pay a dividend. Its free cash flow yield is 23.28%.
| Earnings Yield | 16.13% |
|---|---|
| FCF Yield | 23.28% |
| Buyback Yield | -16.08% |
| Shareholder Yield | -16.08% |
Peer Position
Against 11 similar companies, NRIX has the lowest P/S.
P/S RatioPeer median 6.8x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +24.54%
| P/S Ratio | 2.3x vs 6.8x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +738.76% vs +24.54% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NRIX
What is NRIX's market cap?
Nurix Therapeutics has a market cap of $1.61B. Its enterprise value, which adds debt and subtracts cash, is $889.01M.
What is NRIX's P/E ratio?
Nurix Therapeutics has a trailing P/E ratio of 6.2x and a forward P/E of 5.3x.
How many shares of NRIX are outstanding?
Nurix Therapeutics has 111.56M shares outstanding. The count is up 32.56% from a year earlier.
Does NRIX pay a dividend?
No. Nurix Therapeutics does not pay a dividend.
How much debt does NRIX have?
Nurix Therapeutics has $0 of total debt and $720.24M of cash and equivalents, a net cash position of $720.24M.
NRIX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors